In preclinical studies, it was found that new peptides produced as a result of non-synonymous mutations, among the passenger gene mutations in cancer cells, are presented as neoantigens by the major histocompatibility complex (MHC) of the surface of antigen-presenting cells and may be recognized as non-self by infiltrating immune cells [8, 9]. The gene discussed is HLA-C; the disease is cancer.